Myriad Genetics (MYGN) News Today $14.19 -0.79 (-5.27%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$14.28 +0.08 (+0.59%) As of 02/21/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Peregrine Capital Management LLC Boosts Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)Peregrine Capital Management LLC boosted its position in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 12.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 342,845 shares of the company's stFebruary 20 at 4:20 AM | marketbeat.comMyriad Genetics Included in Forbes America’s Best Employers 2025 ListFebruary 19 at 10:28 AM | markets.businessinsider.comMyriad Genetics Included in Forbes America's Best Employers 2025 ListFebruary 19 at 8:30 AM | globenewswire.comMyriad Genetics (MYGN) to Release Quarterly Earnings on TuesdayMyriad Genetics (NASDAQ:MYGN) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.com3 Reasons to Sell MYGN and 1 Stock to Buy InsteadFebruary 18, 2025 | finance.yahoo.comMyriad Genetics, Inc. (NASDAQ:MYGN) Receives $22.00 Average Target Price from BrokeragesFebruary 15, 2025 | americanbankingnews.comMyriad Genetics (NASDAQ:MYGN) Trading Up 8.3% - Still a Buy?Myriad Genetics (NASDAQ:MYGN) Shares Up 8.3% - Still a Buy?February 14, 2025 | marketbeat.comCraig-Hallum Initiates Coverage of Myriad Genetics (MYGN) with Buy RecommendationFebruary 13, 2025 | msn.comCraig-Hallum bulish on Myriad Genetics, initiates with a BuyFebruary 12, 2025 | markets.businessinsider.comMyriad Genetics initiated with a Buy at Craig-HallumFebruary 12, 2025 | markets.businessinsider.comCraig Hallum Begins Coverage on Myriad Genetics (NASDAQ:MYGN)Craig Hallum initiated coverage on shares of Myriad Genetics in a research report on Wednesday. They issued a "buy" rating and a $29.00 target price on the stock.February 12, 2025 | marketbeat.comMyriad Genetics, Inc. (NASDAQ:MYGN) Given Average Recommendation of "Hold" by AnalystsShares of Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) have received a consensus rating of "Hold" from the thirteen analysts that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, seven have assigned a holFebruary 10, 2025 | marketbeat.comMyriad Genetics, Inc.: Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer TestFebruary 7, 2025 | finanznachrichten.deMyriad Genetics, Inc.: Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) AssayFebruary 7, 2025 | finanznachrichten.deMyriad Genetics, CancerCARE for Life announce agreementFebruary 7, 2025 | markets.businessinsider.comMyriad Genetics, INTERLINK Partner To Enhance Access To Hereditary Cancer TestingFebruary 7, 2025 | markets.businessinsider.comJennison Associates LLC Raises Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)Jennison Associates LLC boosted its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 144.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 59,015 shares of the company's stock after acquiring an additiFebruary 7, 2025 | marketbeat.comMyriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer TestFebruary 6, 2025 | globenewswire.comMyriad Genetics announce collab with LumeaFebruary 6, 2025 | markets.businessinsider.comMyriad Genetics secures patents for cancer MRD testsFebruary 5, 2025 | msn.comMyriad Genetics issued two new patents from USPTOFebruary 5, 2025 | markets.businessinsider.comMyriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) AssayFebruary 5, 2025 | globenewswire.comMyriad Genetics Inc (MYGN) Partners with Lumea Inc. to Enhance Molecular Diagnostic TestingFebruary 5, 2025 | gurufocus.comMyriad Genetics and Lumea Inc. Announce Integration of Advanced Molecular Diagnostic Tests into Digital Pathology Platform BxLink™February 5, 2025 | quiverquant.comMyriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink IntegrationFebruary 5, 2025 | globenewswire.comMyriad Genetics price target lowered to $14 from $24 at Piper SandlerJanuary 30, 2025 | markets.businessinsider.comMyriad Genetics (NASDAQ:MYGN) Given New $14.00 Price Target at Piper SandlerPiper Sandler reduced their price target on shares of Myriad Genetics from $24.00 to $14.00 and set a "neutral" rating on the stock in a research report on Thursday.January 30, 2025 | marketbeat.comFifth Third Bancorp Sells 23,296 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)Fifth Third Bancorp trimmed its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 29.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 55,315 shares of the company's stock after selling 23,296 shares during theJanuary 30, 2025 | marketbeat.comMyriad Genetics Inc (MYGN) Unveils Groundbreaking Prenatal Screening ResearchJanuary 29, 2025 | gurufocus.comMyriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine ConferenceJanuary 29, 2025 | markets.businessinsider.comMyriad Genetics Unveils Groundbreaking Eight Weeks' Gestation NIPT Study Results at Society for Maternal-Fetal Medicine ConferenceJanuary 29, 2025 | globenewswire.comThe Goldman Sachs Group Issues Pessimistic Forecast for Myriad Genetics (NASDAQ:MYGN) Stock PriceThe Goldman Sachs Group decreased their price target on shares of Myriad Genetics from $29.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday.January 28, 2025 | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Reaches New 12-Month Low - Here's WhyMyriad Genetics (NASDAQ:MYGN) Hits New 12-Month Low - Here's WhyJanuary 23, 2025 | marketbeat.comMyriad Genetics stock hits 52-week low at $12.16 amid market challengesJanuary 23, 2025 | msn.comMyriad Genetics Inc (MYGN) Launches Educational Website on Prenatal Genetic TestingJanuary 23, 2025 | gurufocus.comMyriad Genetics Introduces Online Prenatal Genetic Testing ResourceJanuary 23, 2025 | globenewswire.comLeerink Partnrs Comments on Myriad Genetics FY2024 EarningsMyriad Genetics, Inc. (NASDAQ:MYGN - Free Report) - Leerink Partnrs boosted their FY2024 EPS estimates for Myriad Genetics in a report released on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings per share of ($0.28) for the year, up fromJanuary 23, 2025 | marketbeat.comLeerink Partners Sticks to Their Hold Rating for Myriad Genetics (MYGN)January 22, 2025 | markets.businessinsider.comMyriad Genetics announces hereditary cancer risk assessment study publishedJanuary 22, 2025 | markets.businessinsider.comMyriad Genetics Study Shows Increased Completion Rates for Hereditary Cancer Testing Through Online Screening and Education ToolsJanuary 21, 2025 | quiverquant.comMyriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & GynecologyJanuary 21, 2025 | globenewswire.comMyriad Genetics (NASDAQ:MYGN) Updates FY 2024 Earnings GuidanceMyriad Genetics (NASDAQ:MYGN) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.140-0.150 for the period, compared to the consensus estimate of 0.130. The company also issued revenue guidance of $836.0 millionillion-$838.0 millionillion, compared to the consensus estimate of $840.2 millionillion.January 19, 2025 | marketbeat.comMyriad Genetics: Navigating Through A SetbackJanuary 16, 2025 | seekingalpha.comTD Cowen Sticks to Its Hold Rating for Myriad Genetics (MYGN)January 16, 2025 | markets.businessinsider.comMyriad Genetics: Sell Rating Maintained Amid Mixed Financial Outlook and Limited CatalystsJanuary 16, 2025 | markets.businessinsider.comMyriad Genetics (NASDAQ:MYGN) Given "Equal Weight" Rating at StephensStephens reaffirmed an "equal weight" rating and issued a $20.00 target price on shares of Myriad Genetics in a research report on Thursday.January 16, 2025 | marketbeat.comMyriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from AnalystsShares of Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) have been given a consensus recommendation of "Hold" by the twelve analysts that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, six have issued a hold ratinJanuary 16, 2025 | marketbeat.comMyriad Genetics sees Q4 adjusted EPS 3c-4c, consensus 3cJanuary 15, 2025 | msn.comMyriad Genetics sees FY25 adjusted EPS 7c-11c, consensus 9cJanuary 15, 2025 | msn.comMyriad Genetics Reports Preliminary Q4 Results; Issues 2025 OutlookJanuary 15, 2025 | markets.businessinsider.com Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address MYGN Media Mentions By Week MYGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MYGN News Sentiment▼0.410.60▲Average Medical News Sentiment MYGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MYGN Articles This Week▼66▲MYGN Articles Average Week Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IONS News FOLD News LGND News BCRX News DVAX News GERN News CLDX News MNKD News NVAX News INVA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MYGN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
